Home > Insider Trading > Filing (0001491519-19-000001)

Filing Details

Accession Number:: 0001491519-19-000001
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-01-25 14:49:18
Reporting Period:: 2019-01-23

Accepted Time:: 2019-01-25 14:49:18
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
896747	American Bio Medica Corp	ABMC	Pharmaceutical Preparations (2834)	141702188

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1491519	Chaim Davis	80 Brainard Road West Hartford CT 06117		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares	Acquisiton	2019-01-23	38,993	$0.08	132,536	No	4	A	Direct
Common Shares	Acquisiton	2019-01-23	500,000	$0.10	2,449,915	No	4	P	Indirect	By Revach Fund, LP

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	P	Indirect	By Revach Fund, LP

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Non-Statutory Stock Option	Acquisiton	2013-04-26	50,000	$0.18	50,000	$0.18

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
50,000	2014-04-26	2023-04-26	No	4	J	Direct

Footnotes

38,993 shares of restricted stock were issued to Davis as compensation for his attendance at a meeting of the Company's Board of Directors held in January 2019. This stock issuance is in accordance with the director compensation structure approved by the Company's Board of Directors on March 22, 2018 (as indicated in the Company's Proxy Statement filed with the Commission on April 20, 2018).
The volume weighted average price of the Company's common shares for the 10 days preceding the issuance was $0.0833 per share.
These restricted shares of common stock were issued in connection with a private placement of up to 2,000,000 units of common stock as disclosed in a Current Report on Form 8-K filed with the Commission on December 24, 2018. Due to a technical delay, the actual issuance of the shares was not affected until January 25, 2019.
The restricted common shares were issued in connection with a private placement completed on December 24, 2018. The Revach Fund, LP was one of the accredited investors who participated in the private placement. 500,000 units were purchased at $0.10 per share; resulting in a total purchase price of $50,000. Davis is a managing member of Revach Group, LLC which operates as the general partner for the Revach Fund,LP. Davis serves as the Chairman of the Board of the Company.
The price per unit in the private placement was $0.10 per share.
The common shares are in the name of Revach Fund, LP. The reporting person (Davis) is a managing member of Revach Group, LLC which operates as the general partner for the Revach Fund, LP.
This non-statutory stock option was previously reported on a Form 3 filed by Davis on April 19, 2018.This stock option is being re-stated on this Form 4. It is not a new award.